- Home
- POR vs GPCR Comparison
POR vs GPCR Comparison
Compare POR & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | POR | GPCR |
|---|---|---|
| Founded | 1889 | 2016 |
| Country | United States | United States |
| Employees | 2915 | N/A |
| Industry | Electric Utilities: Central | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.3B |
| IPO Year | 1994 | 2023 |
Fundamental Metrics
Financial Performance| Metric | POR | GPCR |
|---|---|---|
| Price | $52.09 | $57.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $48.09 | ★ $104.64 |
| AVG Volume (30 Days) | ★ 1.5M | 691.8K |
| Earning Date | 05-20-2026 | 05-29-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $3,576,000,000.00 | N/A |
| Revenue This Year | $6.68 | N/A |
| Revenue Next Year | $5.56 | N/A |
| P/E Ratio | $18.78 | ★ N/A |
| Revenue Growth | ★ 3.95 | N/A |
| 52 Week Low | $39.55 | $13.24 |
| 52 Week High | $54.39 | $94.90 |
Technical Indicators
Market Signals| Indicator | POR | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 31.66 |
| Support Level | $47.25 | $18.36 |
| Resistance Level | $54.36 | $93.91 |
| Average True Range (ATR) | 0.85 | 2.92 |
| MACD | -0.28 | -0.67 |
| Stochastic Oscillator | 13.91 | 23.64 |
Price Performance
Historical ComparisonAbout POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 300 megawatts of energy storage.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.